Navigation Links
Nektar's PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Date:5/12/2008

de(TM), a novel, synthetic, peptide-based erythropoiesis-stimulating agent (ESA), is a product candidate that has demonstrated the ability to stimulate the production of red blood cells. If proven safe and effective in clinical trials, it may offer physicians and patients an alternative therapy to recombinant erythropoietin, a hormone that stimulates red blood cell formation.

Affymax and Takeda are collaborating on the development of Hematide(TM). The product will be commercialized in the European Union by Takeda. Affymax is conducting Phase 3 clinical trials for Hematide(TM) to treat anemia in chronic renal failure indications. Takeda is also focusing on a recently initiated Phase 1 clinical trial to evaluate Hematide(TM) to treat chemotherapy-induced anemia in prostate, breast and non-small cell lung cancer patients. Hematide(TM) is a trademark of Affymax.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of Hematide(TM), the potential of Nektar's PEGylation Technology, and the overall prospects for Nektar's business. These forward-looking statements involve important risks and uncertainties, including but not limited to: (i) because Hematide(TM) is still in clinical development, the risk of failure is high and can occur at any stage due to many factors including but not limited to safety and efficacy considerations; (ii) Takeda and Affymax may fail to obtain regulatory approval for Hematide(TM) in one or more indications; (iii) if Hematide(TM) does receive regulatory approval, Nektar's actua
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical
3. QLT reports initial proof of concept data for punctal plug delivery technology
4. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Entrust Chairman, President and CEO Bill Conner to Present at 8th Annual State of Technology Luncheon
7. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
8. Guided Surgery Technology Gaining Popularity in the Dental Implant Market
9. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
10. eResearchTechnology Reports First Quarter 2008 Results
11. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... Calif. , March 3, 2015 AtheroNova Inc. ... AtheroNova Operations, Inc., filed voluntary petitions under Chapter 11 of ... District of California , Santa ... 2015. The Company,s Chapter 11 cases are expected to be ... including a Bankruptcy Court supervised asset sale process, for all ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Genedata, ... drug discovery and life science research, today announced ... (TM) enterprise platform for use at Pfizer biopharma ... Europe. Genedata is supporting Pfizer’s global deployment and ... (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "RNAi - Technologies, Markets and ... Because of its ability to silence any gene once ... the research tool to discriminate gene function. After the ... designed to target every gene in the genome and ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3
... July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... research,and development outsourcing company with operations in ... Warburg Pincus, the global private equity,firm, has ... from affiliates,of United Overseas Bank., (Logo: ...
... DIEGO, July 14 NuVasive, Inc. (Nasdaq:,NUVA), a medical ... treatments for the spine, announced today,details relating to its ... Thursday, July 24, 2008 after the close of the ... Thursday, July 24, 2008 at 5:30,p.m. ET / 2:30 ...
... Support, FALLS CHURCH, Va., July 14 CSC ... LLC (DVC), a CSC company, has,received a contract from ... of the National Institutes of Health, to establish,and operate ... The contract is valued at approximately $32.3 million ...
Cached Biology Technology:Warburg Pincus Acquires 5.4% of WuXi PharmaTech's Outstanding Ordinary Shares from United Overseas Bank 2Warburg Pincus Acquires 5.4% of WuXi PharmaTech's Outstanding Ordinary Shares from United Overseas Bank 3NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results 2NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results 3CSC's DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit 2CSC's DVC Wins $32.3 Million NIAID Contract to Establish Phase 1 Clinical Trial Unit 3
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... and POINT ROBERTS, Washington , January 20, ... leading sectors including technology and tech stocks, releases video from ... master pickpocket and security consultant Apollo Robbins . ... talks about the Wocket™ biometric smart wallet, a product of ...
(Date:1/22/2015)... , January 22, 2015 , ... tenth year  The European Patent Office to present a ... Two British nominations to be featured: Christofer Toumazou and ... featuring former finalists and winners of the Award   ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... a protein channel helps nerve sensors in blood vessels keep ... ASIC2, the sensors are unable to send the brain the ... finding, which was based in animal models, is important because ... high blood pressure (hypertension). The study results appear in the ...
... marine turtles around the world,s oceans will be available to ... launched by the University of Exeter. Noelle and ... Gabon, Western Central Africa. The research team has fitted each ... scientists to monitor their precise movements and observe where and ...
... one of its international professorships to John Leslie, professor ... State University. The society has awarded Leslie an ... visiting professor at the Universidad Nacional de Rio Cuarto ... Workshop in March 2010. The workshop helps participants ...
Cached Biology News:Study shows a key protein helps control blood pressure 2Study shows a key protein helps control blood pressure 3Turtles' Christmas journey tracked by scientists 2
Form: Concentrated Applications: ELISA...
Request Info...
Form: Ready to use Applications: ELISA...
... have hydrophobic plastic supports that retain stiffness ... toxic/hazardous solutions. Paper segments on each strip ... solution. Complementary indicator charts provide clear comparison. ... 1pH units; In packs of 100; each ...
Biology Products: